Biotech Catalysts to Watch: Key Developments Through 2026

With the end of 2026 on the horizon, seven biotech catalysts stand out as potential market movers. Drugs like IGALMI® (BTAI) and EYP-1901 (EYPT) are set for pivotal moments with upcoming decisions and data releases. These developments offer unique opportunities for investors and industry professionals, reflecting ongoing innovation in biotech.

The full biotech catalysts to watch

IGALMI® (dexmedetomidine) - PDUFA Date: November 14, 2026

IGALMI® (BTAI) is in the spotlight with its PDUFA date on November 14, 2026. This selective α2A-adrenergic receptor agonist is already approved for acute agitation in bipolar disorders and schizophrenia since April 2022. The upcoming decision concerns a supplemental NDA to expand its use for Alzheimer's-related agitation, a critical need due to limited treatment options. The approval probability for this new indication is estimated between 5-15%, underscoring regulatory uncertainty. IGALMI's non-invasive, fast-acting formulation as an orally dissolving sublingual film makes it a strong contender in a market eager for effective agitation management. However, risks include cardiovascular concerns and potential adverse effects in vulnerable groups. The decision on the supplemental NDA could significantly alter IGALMI's market potential, making it a key focus for investors.

EYP-1901 (Vorolanib Intravitreal Insert) - Phase 3 Results Due: September 24, 2026

EYP-1901 (EYPT) emerges as a major catalyst with Phase 3 results expected on September 24, 2026. This sustained-release intravitreal insert targets neovascular age-related macular degeneration (nAMD). The LUGANO and LUCIA studies will compare EYP-1901 to aflibercept, a standard treatment, with around 800 patients enrolled. Demonstrating noninferiority to aflibercept while reducing treatment burden is crucial. The approval probability stands at 58%, indicating potential in a market valued between $9-12 billion globally. The absence of Fast Track or Breakthrough Therapy designations raises questions about its competitive edge. Maintaining visual acuity and ensuring patient compliance through fewer injections are key. Investors should note how EYP-1901 handles regulatory scrutiny, as results could validate its innovative approach or reveal challenges.

TPST-2003 - Phase 1/2 and IND Filing: December 31, 2026

TPST-2003 (TPST) is at a critical juncture with its Phase 1/2 trial and IND filing set for December 31, 2026. This drug targets relapsed or refractory multiple myeloma, an area with high unmet needs. While details about the trials are limited, TPST-2003's potential to offer a new treatment pathway could appeal to investors, given the demand for innovative therapies in hematological malignancies. The current decline of -6.9% indicates market skepticism, presenting an opportunity for calculated risk-takers. The lack of concrete approval probability adds complexity, but anticipation around trial outcomes could spark interest as the date nears. Positive results might lead to a significant reassessment of TPST's market position.

Deramiocel (CAP-1002) - Multiple Pivotal Dates: October 3 & November 22, 2026

Deramiocel (CAP-1002) from Capricor Therapeutics is a key catalyst with pivotal dates on October 3 and November 22, 2026. This therapy targets Duchenne muscular dystrophy (DMD), a rare and devastating condition. The upcoming dates relate to different trials, with the November date having a moderate approval probability, indicating a reasonable chance of success despite inherent risks. DMD's lack of sufficient treatment options means positive outcomes could significantly impact patient care and market dynamics. The October trial has a low approval probability, indicating uncertainty. Investors should weigh these catalysts carefully, as trial outcomes could dramatically shift Capricor's trajectory. DMD therapy market emotions and potential regulatory approval make this an intriguing scenario to monitor.

SIL204 - Low PoA, High Stakes: December 31, 2026

SIL204 (SLXN) represents a significant catalyst with a decision due on December 31, 2026. This drug targets locally advanced pancreatic cancer, a notoriously tough indication. The low approval probability suggests a challenging path. Current market sentiment reflects this uncertainty, shown by weak run-up metrics. Investors should be cautious, weighing the risk-reward ratio for SIL204. The stakes are high, and any regulatory decision could significantly impact SLXN's share price and the broader landscape of pancreatic cancer treatments. Monitoring insider activity and trial updates will be crucial as the decision date approaches.

ZYNLONTA (loncastuximab tesirine-lpyl) - LOTIS-5 Trial: December 31, 2026

ZYNLONTA (ADCT) is set to be a pivotal catalyst with LOTIS-5 trial results expected on December 31, 2026. This combination therapy with rituximab targets 2L+ diffuse large B-cell lymphoma (DLBCL), an area with significant unmet need. The approval probability is high, reflecting confidence in its potential to provide a meaningful treatment option. The current market suggests optimism, and positive results could trigger a strong upward movement in ADCT's stock. Integrating ZYNLONTA with established therapies like rituximab could redefine DLBCL treatment protocols, making this trial a key event for investors. The data implications could extend beyond ADCT's immediate market, influencing broader hematology treatment strategies.

The bottom line

Staying informed on these catalysts is crucial for making strategic investment decisions in the biotech sector.